Switch theme
Sign up to access all valuation multiples
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
1933
34.1K+
LTM Revenue $47.8B
LTM EBITDA $8.7B
$160B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bristol-Myers Squibb has a last 12-month revenue of $47.8B and a last 12-month EBITDA of $8.7B.
In the most recent fiscal year, Bristol-Myers Squibb achieved revenue of $48.3B and an EBITDA of $3.2B.
Bristol-Myers Squibb expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bristol-Myers Squibb valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $45.0B | $48.3B | XXX | XXX | XXX |
| Gross Profit | $36.0B | $34.3B | XXX | XXX | XXX |
| Gross Margin | 80% | 71% | XXX | XXX | XXX |
| EBITDA | $19.4B | $3.2B | XXX | XXX | XXX |
| EBITDA Margin | 43% | 7% | XXX | XXX | XXX |
| Net Profit | $6.3B | $8.0B | XXX | XXX | XXX |
| Net Margin | 14% | 17% | XXX | XXX | XXX |
| Net Debt | $30.2B | $28.3B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Bristol-Myers Squibb's stock price is $59.
Bristol-Myers Squibb has current market cap of $120B, and EV of $160B.
See Bristol-Myers Squibb trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $160B | $120B | XXX | XXX | XXX | XXX | $2.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Bristol-Myers Squibb has market cap of $120B and EV of $160B.
Bristol-Myers Squibb's trades at 3.4x LTM EV/Revenue multiple, and 18.4x LTM EBITDA.
Analysts estimate Bristol-Myers Squibb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bristol-Myers Squibb and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $160B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | 50.5x | XXX | XXX | XXX |
| P/E | -13.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 11.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBristol-Myers Squibb's NTM/LTM revenue growth is -6%
Bristol-Myers Squibb's revenue per employee for the last fiscal year averaged $1.4M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Bristol-Myers Squibb's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bristol-Myers Squibb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bristol-Myers Squibb and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -84% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 1% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 59% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bristol-Myers Squibb acquired XXX companies to date.
Last acquisition by Bristol-Myers Squibb was XXXXXXXX, XXXXX XXXXX XXXXXX . Bristol-Myers Squibb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bristol-Myers Squibb founded? | Bristol-Myers Squibb was founded in 1933. |
| Where is Bristol-Myers Squibb headquartered? | Bristol-Myers Squibb is headquartered in United States of America. |
| How many employees does Bristol-Myers Squibb have? | As of today, Bristol-Myers Squibb has 34.1K+ employees. |
| Who is the CEO of Bristol-Myers Squibb? | Bristol-Myers Squibb's CEO is Dr. Christopher S. Boerner, PhD. |
| Is Bristol-Myers Squibb publicy listed? | Yes, Bristol-Myers Squibb is a public company listed on NYS. |
| What is the stock symbol of Bristol-Myers Squibb? | Bristol-Myers Squibb trades under BMY ticker. |
| When did Bristol-Myers Squibb go public? | Bristol-Myers Squibb went public in 1952. |
| Who are competitors of Bristol-Myers Squibb? | Similar companies to Bristol-Myers Squibb include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bristol-Myers Squibb? | Bristol-Myers Squibb's current market cap is $120B |
| What is the current revenue of Bristol-Myers Squibb? | Bristol-Myers Squibb's last 12-month revenue is $47.8B. |
| What is the current EBITDA of Bristol-Myers Squibb? | Bristol-Myers Squibb's last 12-month EBITDA is $8.7B. |
| What is the current EV/Revenue multiple of Bristol-Myers Squibb? | Current revenue multiple of Bristol-Myers Squibb is 3.4x. |
| What is the current EV/EBITDA multiple of Bristol-Myers Squibb? | Current EBITDA multiple of Bristol-Myers Squibb is 18.4x. |
| What is the current revenue growth of Bristol-Myers Squibb? | Bristol-Myers Squibb revenue growth between 2023 and 2024 was 7%. |
| Is Bristol-Myers Squibb profitable? | Yes, Bristol-Myers Squibb is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
